Anti-CCR4 Antibody and Lenalidomide Combination for T-cell Lymphoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for T-cell lymphoma, particularly those expressing human CC chemokine receptor 4 (CCR4), lack effective therapeutic agents, and there is no approved combination therapy of Lenalidomide with therapeutic antibodies, including anti-CCR4 antibodies, which hampers their clinical efficacy.
Innovation Solution
A pharmaceutical composition comprising a recombinant antibody specifically binding to CCR4 in combination with Lenalidomide, where the antibody has high antibody-dependent cellular cytotoxicity and is administered simultaneously or sequentially with the medicament, either as a fusion antibody or separately, to enhance therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a recombinant anti-CCR4 antibody is used to treat T-cell lymphoma, then antitumor activity is improved, but therapeutic efficacy is insufficient when used alone
Solution Approach 1:
The patent combines a recombinant anti-CCR4 antibody with Lenalidomide to create a synergistic therapeutic regimen. The antibody targets CCR4-expressing T-cell lymphoma cells while Lenalidomide provides immunomodulatory and antiproliferative effects, resulting in enhanced antitumor activity compared to either agent alone.
Solution Approach 2:
The therapeutic composition integrates multiple active components (antibody and Lenalidomide) into a composite treatment formulation. This combination leverages the complementary mechanisms of action between the antibody-mediated cellular cytotoxicity and Lenalidomide's immunomodulatory properties to achieve superior therapeutic efficacy.
2Productivity
If Lenalidomide is combined with therapeutic antibodies, then therapeutic effect is enhanced, but combination therapy is not approved in clinical practice
Solution Approach 1:
The patent provides preclinical data and mechanistic rationale establishing the basis for clinical approval. By demonstrating synergistic antitumor activity in animal models and outlining the biological rationale, the invention prepares the foundation for regulatory approval of this combination therapy.
3Reliability
If combination therapy is implemented, then treatment outcomes are improved, but treatment complexity increases
Solution Approach 1:
The combination of anti-CCR4 antibody and Lenalidomide addresses multiple therapeutic needs simultaneously: the antibody provides targeted cellular cytotoxicity while Lenalidomide contributes immunomodulation and antiangiogenic effects. This multi-functional approach improves treatment outcomes across different aspects of tumor biology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of the recombinant anti-CCR4 antibody and Lenalidomide demonstrates enhanced antitumor activity, as shown in animal models, providing a higher therapeutic effect than either agent alone, while reducing adverse effects and improving treatment outcomes for T-cell lymphoma.
Implementation Method 1
the antibody has high antibody-dependent cellular cytotoxicity
Data Source
AI summary
A pharmaceutical composition, comprising an antibody composition which specifically binds to human CC chemokine receptor 4 (hereinafter also referred to as CCR4) and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament are required. The present invention can provide a pharmaceutical composition comprising a recombinant antibody against CCR4 and at least one medicament; and a pharmaceutical composition for administering in combination of a recombinant antibody against CCR4 and at least one medicament.